Literature DB >> 24916573

The adenocarcinoma cell surface mucin receptor for alpha-fetoprotein: is the same receptor present on circulating monocytes and macrophages? A commentary.

G J Mizejewski1.   

Abstract

The mucin family of proteins is largely expressed on sedentary epithelial cells lining the gastrointestinal, pulmonary, and reproductive tracts and their associated organs and malignant tumors. It is less well-known that mucins are also expressed on circulatory cells of the immune and inflammatory systems, such as monocytes, macrophages, leukemic, and lymphoma cells. The epithelial mucins function in (a) protection and lubrication of mucosal linings, (b) cell adhesion and cell-to-cell contact, (c) cell migration and metastasis, and (d) signal transduction. It would be logical to presume that mucins expressed on circulating mononuclear cells could perform similar functions. Recently, it was proposed that the alpha-fetoprotein (AFP) receptor, known to be present on solid epithelial-derived malignant tumor cells, can be identified as a mucin glycoprotein. Interestingly, it was also reported that AFP binds to a receptor on circulating cells and sedentary tumor cells of lymphoreticular origin, especially monocytes associated with lymphomas and leukemias. The primary objective of the present commentary is to present literature-based evidence that some of the cell surface mucins on sedentary epithelial tumor cells and certain mucins expressed on circulating monocytes/macrophages are identical to the AFP receptor. The secondary objective is to discuss the role of AFP and its derived peptides in the growth suppression of adenocarcinomas and lymphomas using the AFP-mucin receptor concept as a key to the mechanism of tumor growth inhibition.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24916573     DOI: 10.1007/s13277-014-2183-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  48 in total

1.  Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas.

Authors:  Pamela L Beatty; Olivera J Finn
Journal:  Ann N Y Acad Sci       Date:  2013-05       Impact factor: 5.691

2.  Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.

Authors:  Sally J DeNardo; Carol M Richman; Huguette Albrecht; Patricia A Burke; Arut Natarajan; Aina Yuan; Jeff P Gregg; R T O'Donnell; Gerald L DeNardo
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

3.  Expression of mucin (MUC-1) from a mini-Epstein-Barr virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells.

Authors:  E Kilger; G Pecher; A Schwenk; W Hammerschmidt
Journal:  J Gene Med       Date:  1999 Mar-Apr       Impact factor: 4.565

4.  [Clinical significance of the expression of MUC4 mRNA in peripheral blood mononuclear cells of pancreatic cancer patients].

Authors:  Xiao-hui Li; Jiong-xin Xiong; Chun-you Wang
Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao       Date:  2005-10

5.  Receptor-mediated endocytosis and recycling of alpha-fetoprotein in human B-lymphoma and T-leukemia cells.

Authors:  J M Torres; M Geuskens; J Uriel
Journal:  Int J Cancer       Date:  1991-01-02       Impact factor: 7.396

6.  MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Authors:  Takashi Kimura; John R McKolanis; Lynda A Dzubinski; Kazi Islam; Douglas M Potter; Andres M Salazar; Robert E Schoen; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-17

7.  Monoclonal antibodies directed against a widespread oncofetal antigen: the alpha-fetoprotein receptor.

Authors:  R Moro; T Tamaoki; T G Wegmann; B M Longenecker; M P Laderoute
Journal:  Tumour Biol       Date:  1993

8.  MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells.

Authors:  Norishige Yamada; Yukari Nishida; Hideaki Tsutsumida; Tomofumi Hamada; Masamichi Goto; Michiyo Higashi; Mitsuharu Nomoto; Suguru Yonezawa
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

Review 9.  Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior.

Authors:  Suguru Yonezawa; Masamichi Goto; Norishige Yamada; Michiyo Higashi; Mitsuharu Nomoto
Journal:  Proteomics       Date:  2008-08       Impact factor: 3.984

10.  MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells.

Authors:  Takeshi Kawano; Masaki Ito; Deepak Raina; Zekui Wu; Jacalyn Rosenblatt; David Avigan; Richard Stone; Donald Kufe
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

View more
  3 in total

1.  Nonsecreted cytoplasmic alpha-fetoprotein: a newly discovered role in intracellular signaling and regulation. An update and commentary.

Authors:  G J Mizejewski
Journal:  Tumour Biol       Date:  2015-07-12

2.  The alpha-fetoprotein (AFP) third domain: a search for AFP interaction sites of cell cycle proteins.

Authors:  G J Mizejewski
Journal:  Tumour Biol       Date:  2016-07-22

Review 3.  Alpha-Fetoprotein Binding Mucin and Scavenger Receptors: An Available Bio-Target for Treating Cancer.

Authors:  Bo Lin; Qiujiao Wang; Kun Liu; Xu Dong; Mingyue Zhu; Mengsen Li
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.